U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07705035) titled 'DBC-664 in Adult Patients With Solid Tumors Associated' on June 29.
Brief Summary: DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Malignant Germ Cell Tumor
Lun...